mEpoR Knockout/Tg(hEpoR) Mouse Model for Anemia and Renal Function Studies


mEpoR-/- hEpoR+: The mouse Erythropoietin Receptor knockout that contains a human Erythropoietin Receptor transgene can be used to define the potency of recombinant erythropoietin preparations used to treat anemia associated with chronic kidney disease.

Erythropoietin, acting by binding to Erythropoietin receptors (EpoR) on erythroid progenitor cells, is required for erythropoiesis. Absence of erythropoietin or the EpoR in mice interrupts erythropoiesis in the fetal liver and result in death at embryonic day 13.5. An 80-kb human EpoR transgene bred onto a mouse EpoR null background (provided by F. Constantini of Columbia University) restored effective erythropoiesis in the EpoR null mouse. Erythropoietin preparations made utilizing recombinant DNA technology are used in the treatment of anemia in chronic kidney disease and other critical illnesses. The mouse EpoR null mouse containing the human EpoR transgene can be used to define the potency of erythropoietin preparation in humans.

Potential Commercial Applications: Competitive Advantages:
Model for study of anemia and renal function and possible drug screening. 


Development Stage:
Pre-clinical

Inventors:

Constance Noguchi (NIDDK)  ➽ more inventions...


Intellectual Property:
Research Tool - Patent protection is not being pursued for this technology.

Publications:
Yu X, et al. PMID 11435319

Licensing Contact:
Betty Tong, Ph.D.
Email: tongb@niddk.nih.gov
Phone: 301-451-7836

OTT Reference No: E-127-2001-0
Updated: Feb 12, 2015